RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Shanghai Junshi Biosciences Co Stock

Shanghai Junshi Biosciences Co Net Income 2024

Shanghai Junshi Biosciences Co Net Income

-1.12 B CNY

Ticker

688180.SS

ISIN

CNE1000041Z1

In 2024, Shanghai Junshi Biosciences Co's profit amounted to -1.12 B CNY, a -51.1% increase from the -2.28 B CNY profit recorded in the previous year.

The Shanghai Junshi Biosciences Co Net Income history

YEARNET INCOME (undefined CNY)
2029e-
2028e-
2027e-
2026e-
2025e-
2024e-
2023-
2022-
2021-
2020-
2019-
2018-
2017-

Shanghai Junshi Biosciences Co Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Shanghai Junshi Biosciences Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Shanghai Junshi Biosciences Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Shanghai Junshi Biosciences Co’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Shanghai Junshi Biosciences Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Shanghai Junshi Biosciences Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Shanghai Junshi Biosciences Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Shanghai Junshi Biosciences Co’s growth potential.

Shanghai Junshi Biosciences Co Revenue, EBIT and net profit per share

DateShanghai Junshi Biosciences Co RevenueShanghai Junshi Biosciences Co EBITShanghai Junshi Biosciences Co Net Income
2029e5.76 B undefined0 undefined0 undefined
2028e5.25 B undefined1.24 B undefined0 undefined
2027e4.77 B undefined851.49 M undefined0 undefined
2026e3.75 B undefined-995.86 M undefined-205.13 M undefined
2025e2.78 B undefined-1.13 B undefined-518.62 M undefined
2024e1.77 B undefined-1.22 B undefined-1.12 B undefined
20231.5 B undefined-2.48 B undefined-2.28 B undefined
20221.45 B undefined-2.72 B undefined-2.39 B undefined
20214.02 B undefined-594.04 M undefined-720.91 M undefined
20201.59 B undefined-1.68 B undefined-1.67 B undefined
2019775.1 M undefined-774.2 M undefined-747.4 M undefined
20182.9 M undefined-688.1 M undefined-722.9 M undefined
201754.5 M undefined-298.7 M undefined-317.3 M undefined

Shanghai Junshi Biosciences Co stock margins

The Shanghai Junshi Biosciences Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Shanghai Junshi Biosciences Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Shanghai Junshi Biosciences Co.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Shanghai Junshi Biosciences Co's sales revenue. A higher gross margin percentage indicates that the Shanghai Junshi Biosciences Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Shanghai Junshi Biosciences Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Shanghai Junshi Biosciences Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Shanghai Junshi Biosciences Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Shanghai Junshi Biosciences Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Shanghai Junshi Biosciences Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Shanghai Junshi Biosciences Co Margin History

Shanghai Junshi Biosciences Co Gross marginShanghai Junshi Biosciences Co Profit marginShanghai Junshi Biosciences Co EBIT marginShanghai Junshi Biosciences Co Profit margin
2029e57.78 %0 %0 %
2028e57.78 %23.65 %0 %
2027e57.78 %17.85 %0 %
2026e57.78 %-26.53 %-5.46 %
2025e57.78 %-40.74 %-18.66 %
2024e57.78 %-69.07 %-63.15 %
202357.78 %-165.01 %-151.97 %
202263.79 %-187.06 %-164.3 %
202168.74 %-14.76 %-17.91 %
202076.37 %-105.19 %-104.62 %
201988.3 %-99.88 %-96.43 %
201834.48 %-23,727.59 %-24,927.59 %
201790.46 %-548.07 %-582.2 %

Shanghai Junshi Biosciences Co Aktienanalyse

What does Shanghai Junshi Biosciences Co do?

Shanghai Junshi Biosciences Co Ltd is a Chinese company specializing in biopharmaceutical research and development. It was founded in 2012 and is headquartered in Shanghai. The company's business model focuses on the development and manufacturing of innovative biopharmaceutical products. Its goal is to develop therapies for diseases that currently have no satisfactory treatment options. The company utilizes its experience in immuno-oncology and other areas of biopharmaceutical research. It has established different divisions for drug research and development, including immunoncology, inflammation, and infectious diseases. The company has a strong pipeline for developing new oncology drugs. It specializes in the development of monoclonal antibodies that are tailored to specific target processes and can provide customized treatment options for patients. The company's flagship products include Toripalimab, Tuoyi, and several preparations for the treatment of cancers such as lung, breast, stomach, liver, colorectal, and head and neck cancers. Toripalimab is a human monoclonal antibody used to treat advanced, recurrent, or metastatic melanoma. Tuoyi is an antibody that targets the human TNF-alpha protein, which is produced by white blood cells and promotes inflammation in the body. It is approved for the treatment of various rheumatic diseases such as rheumatoid arthritis. The company has also recently launched an RNA vaccine program to combat the COVID-19 virus and has shown its potential. Junshi has tested the first antiviral antibody for COVID-19 in humans. Overall, Shanghai Junshi Biosciences Co Ltd has quickly built a strong portfolio of business activities and established itself as a key player in the Chinese pharmaceutical market. The company is expected to continue playing a leading role in biopharmaceutical research and development in the future. Shanghai Junshi Biosciences Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding Shanghai Junshi Biosciences Co's Profit Margins

The profit margins of Shanghai Junshi Biosciences Co represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Shanghai Junshi Biosciences Co's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Shanghai Junshi Biosciences Co's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Shanghai Junshi Biosciences Co's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Shanghai Junshi Biosciences Co’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Shanghai Junshi Biosciences Co stock

How much profit has Shanghai Junshi Biosciences Co made this year?

Shanghai Junshi Biosciences Co has made -1.12 B CNY this year.

How has the profit developed compared to last year?

The profit has increased by -51.1% compared to last year fallen

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does Shanghai Junshi Biosciences Co publish its earnings?

Shanghai Junshi Biosciences Co publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of Shanghai Junshi Biosciences Co?

The profits of Shanghai Junshi Biosciences Co are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of Shanghai Junshi Biosciences Co?

You can learn more about the earnings of Shanghai Junshi Biosciences Co by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does Shanghai Junshi Biosciences Co pay?

Over the past 12 months, Shanghai Junshi Biosciences Co paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Shanghai Junshi Biosciences Co is expected to pay a dividend of 0 CNY.

What is the dividend yield of Shanghai Junshi Biosciences Co?

The current dividend yield of Shanghai Junshi Biosciences Co is .

When does Shanghai Junshi Biosciences Co pay dividends?

Shanghai Junshi Biosciences Co pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Shanghai Junshi Biosciences Co?

Shanghai Junshi Biosciences Co paid dividends every year for the past 0 years.

What is the dividend of Shanghai Junshi Biosciences Co?

For the upcoming 12 months, dividends amounting to 0 CNY are expected. This corresponds to a dividend yield of 0 %.

In which sector is Shanghai Junshi Biosciences Co located?

Shanghai Junshi Biosciences Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Shanghai Junshi Biosciences Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Shanghai Junshi Biosciences Co from 12/5/2024 amounting to 0 CNY, you needed to have the stock in your portfolio before the ex-date on 12/5/2024.

When did Shanghai Junshi Biosciences Co pay the last dividend?

The last dividend was paid out on 12/5/2024.

What was the dividend of Shanghai Junshi Biosciences Co in the year 2023?

In the year 2023, Shanghai Junshi Biosciences Co distributed 0 CNY as dividends.

In which currency does Shanghai Junshi Biosciences Co pay out the dividend?

The dividends of Shanghai Junshi Biosciences Co are distributed in CNY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Shanghai Junshi Biosciences Co

Our stock analysis for Shanghai Junshi Biosciences Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Shanghai Junshi Biosciences Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.